Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2022-12-09
- Target Recruit Count
- 15
- Registration Number
- NCT04570410
- Locations
- 🇨🇳
The first affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT04541277
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-08-02
- Target Recruit Count
- 10
- Registration Number
- NCT04539444
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 460
- Registration Number
- NCT04501523
- Locations
- 🇨🇳
Sunyat-sen Memorial Hospital, Guandong, Guangdong, China
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 123
- Registration Number
- NCT04486391
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 222
- Registration Number
- NCT04443543
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Cencer, Shanghai, Shanghai, China
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04405674
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 64
- Registration Number
- NCT04401800
- Locations
- 🇨🇳
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 453
- Registration Number
- NCT04379635
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Capital Medical University Xuanwu Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital - Oncology, Beijing, Beijing, China
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 46
- Registration Number
- NCT04318080
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.